Table 1.

Characteristics of the included published studies.

Article	Clinical trials registration	Phase	Center	Study population	Intervention group	Control group	Age range	Sample size
								Intervention group	Control group
Cabral et al., 2022a [17]	NCT04668235	3	Single-center	Patients with moderate COVID-19	Azvudine 5 mg + standard treatment	Placebo + standard treatment	18 Years and older	89	83
Cabral et al., 2022b [18]	NCT05033145	3	Single-center	Patients with mild COVID-19	Azvudine 5 mg + standard treatment	Placebo + standard treatment	18 Years and older	143	138
Ren et al., 2020 [19]	ChiCTR2000029853	3	Single-center	Patients with mild and common COVID-19	Azvudine 5 mg + standard treatment	Placebo + standard treatment	18 Years and older	10	10
China, 2022 [20]	NCT04746183	3	Multi-center	Patients with mild and common COVID-19	Azvudine 5 mg + standard treatment	Placebo + standard treatment	18 Years and older	174	174
Russia, 2022 [20]	NR	NR	Multi-center	Patients with moderate COVID-19	Azvudine 5 mg	Placebo	18 Years and older	157	157

NR: Not reported.